TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models

[1] Okano M(1999)DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 247-257

[2] Bell DW(2001)Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription EMBO J 20 2536-2544

[3] Haber DA(2001)Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin J Biol Chem 276 32282-32287

[4] Li E(2010)DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2424-2433

[5] Fuks F(2014)DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Leukemia 28 1774-1783

[6] Burgers WA(2012)DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia Leukemia 26 1106-1107

[7] Godin N(2014)Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents Leuk Lymphoma 55 1925-1929

[8] Kasai M(2013)TETonic shift: biological roles of TET proteins in DNA demethylation and transcription Nat Rev Mol Cell Biol 14 341-356

[9] Kouzarides T(2015)Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis Genes Dev 29 910-922

[10] Bachman KE(2009)Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 838-842

[1] Okano M(1999)DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 247-257

[2] Bell DW(2001)Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription EMBO J 20 2536-2544

[3] Haber DA(2001)Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin J Biol Chem 276 32282-32287

[4] Li E(2010)DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2424-2433

[5] Fuks F(2014)DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Leukemia 28 1774-1783

[6] Burgers WA(2012)DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia Leukemia 26 1106-1107

[7] Godin N(2014)Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents Leuk Lymphoma 55 1925-1929

[8] Kasai M(2013)TETonic shift: biological roles of TET proteins in DNA demethylation and transcription Nat Rev Mol Cell Biol 14 341-356

[9] Kouzarides T(2015)Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis Genes Dev 29 910-922

[10] Bachman KE(2009)Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 838-842